These findings suggest that once-weekly DPP-4 inhibitors may be associated with a relatively higher risk of ‘musculoskeletal and connective tissue disorders’, while the risk of other adverse events appears comparable between the two groups. This evidence concerns the gene DPP4 and connective tissue disorder.